Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT03551626
Title	Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes (COMBI-APlus)
Acronym	COMBI-APlus
Recruitment	Completed
Gender	both
Phase	Phase III
Variant Requirements	Yes
Sponsors	Novartis Pharmaceuticals
Indications	skin melanoma
Therapies	Dabrafenib + Trametinib
Age Groups:	adult \| senior
Covered Countries	TUR \| SWE \| SVN \| SVK \| POL \| NOR \| LVA \| LTU \| ITA \| ISR \| HUN \| GRC \| GBR \| FRA \| FIN \| CZE \| CAN \| BRA \| AUS \| ARG